Phos4nova B.V.

Over Phos4nova B.V.

Purpose: We are driven by the belief that one day, no one will have to fear a severe diagnosis and the suffering caused by life-altering conditions, such as a late-stage cancer or progressing Alzheimer’s disease. Vision: We want to create a world where efficient and sustainable treatments are accessible to everyone, disrupting the status quo in healthcare. Mission: We are developing a unique polymer technology that empowers clinicians to obtain early diagnoses and establish efficient personalized therapies, and enables scientists to innovate therapeutic materials including nanomedicines, and medical devices.

We develop world‘s first polymers that produce inherent MRI signal based on unique biodegradable, bioispired polyphosphoester (PPE) technology.

-The first and only biocompatible and biodegradable MRI contrast agent that utes direct imaging of non-radioactive 31P directly in polymer backbone. -Unique molecular design eliminates the need for toxic or persistent substances like heavy-metal chelates, ensuring safety and sustainability. -Background-Free 31P Detection and Quantification: Clear signal detection in a distinct "color", completely independent of anatomical background allows for precise visualization and localization -Signal quantification enables precise analysis, providing valuable insights for research and clinical applications -Unique, versatile uas a building block for label-free nanomedicines and biomaterials with inherent imaging capabilities

Are you developing nanomedicines, biomaterials or imaging agents? Are you struggling with ill-defined polymers and looking for tailor made materials? Or do you experience trouble with labeling you nanocarriers for imaging and want to save time?

Reach out to us to learn more: contact@phos4nova.eu

Trefwoorden

• Biomaterials
• Imaging Agents
• Nanomedicine
• Polymers
• Polyphosphoesters

Adres

• Hoofdkantoor

  EnschedeOverijssel, Nederland

Team per functiegebied

Gebaseerd op 2 openbare functieprofielen, stand van 3 september 2026.

• Engineering / Software Development1
• Research / R&D1